Aurobindo Pharma Ltd has received final approval from the US Food and Drug Administration (US FDA) to manufacture and market ramipril capsules USP 1.25mg, 2.5mg, 5mg and 10mg

Ramipril capsules USP 1.25mg, 2.5mg, 5mg and 10mg is the generic equivalent of Altace capsules 1.25mg, 2.5mg, 5mg and 10mg of King Pharmaceuticals Inc. Ramipril capsules are indicated for the treatment of hypertension and falls under the cardiovascular (CVS) therapeutic segment. It has a market size of approximately USD 95 million for the twelve months ending September 2010 according to IMS and will be launched soon.

Aurobindo now has a total of 138 abbreviated new drug application (ANDA) approvals, including 108 final approvals and 30 tentative approvals from the US FDA.